There is also the 202 trial in late stage MSA patients. Not sure when results will be presented for this trial but most likely will be in the 2nd half of this year. Immediate goal I should think would be to obtain AA from the FDA. If this happens there will be much more interest in ATH form a Pharma point of view. I am sure they will also start looking at ATH434 in Parkinson disease patients. Lots on their plate.
ATH Price at posting:
1.2¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)